1601. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial chemoembolization of hepatocellular carcinomaPeter Popović, Ana Leban, Klara Kregar, Manca Garbajs, Rok Dežman, Matjaž Bunc, 2018, original scientific article Keywords: hepatocellular carcinoma, computed tomography perfusion imaging, drug-eluting beads transarterial chemoembolization, response to treatment, survival
Published in DiRROS: 11.06.2024; Views: 511; Downloads: 270
 Full text (1,59 MB)
This document has many files! More... |
1602. |
1603. |
1604. Optic nerve ultrasound for fluid status assessment in patients with severe preeclampsiaGabrijela Bržan Šimenc, Jana Ambrožič, Katja Prokšelj, Nataša Tul, Marta Cvijić, Tomislav Mirković, Helmut Karl Lackner, Miha Lučovnik, 2018, original scientific article Keywords: preeclampsia, fluid status, ocular ultrasound, optic nerve sheath diameter, lung ultrasound, comet tail (B-lines) sign
Published in DiRROS: 11.06.2024; Views: 291; Downloads: 174
Full text (418,21 KB)
This document has many files! More... |
1605. Pharmacogenomic markers of glucorticoid responses in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemiaVladimir Gasic, Branka Zukic, Biljana Stanković, Dragana Janić, Lidija Dokmanovic, Jelena Lazic, Nada Krstovski, Vita Dolžan, Janez Jazbec, Sonja Pavlovič, Nikola Kotur, 2018, original scientific article Keywords: pharmacogenomics, childhood ALL, glucocorticoids, glucocorticoid receptor gene, glutathione S-transferase genes, multidrug resistance 1 gene
Published in DiRROS: 11.06.2024; Views: 298; Downloads: 101
Full text (339,19 KB) |
1606. Localization patterns of cathepsins K and X and their predictive value in glioblastomaBarbara Breznik, Clara Limbaeck Stanic, Andrej Porčnik, Andrej Blejec, Miha Koprivnikar Krajnc, Roman Bošnjak, Janko Kos, Cornelis J. F. van Noorden, Tamara Lah Turnšek, 2018, original scientific article Keywords: cathepsins, glioblastoma, immunohistochemistry, patient survival, cancer stem cell niches
Published in DiRROS: 11.06.2024; Views: 260; Downloads: 185
Full text (1,91 MB) |
1607. Electrochemotherapy with bleomycin of different types of cutaneous tumours in a ferret (Mustela putorius furo)Joško Račnik, Tanja Švara, Marko Zadravec, Mitja Gombač, Maja Čemažar, Gregor Serša, Nataša Tozon, 2018, original scientific article Abstract: Mast cell tumour, sebaceous gland adenoma, and less common squamous papilloma are skin tumours in ferrets (Mustela putorius furo), and early excisional surgery is usually the treatment of choice. The aim of our study was to investigate the effectiveness of electrochemotherapy (ECT), a new, minimally invasive non-surgical method, as first treatment option of different types of ferret skin tumours located on surgically difficult sites. Materials and methods A 5-year-old castrated male ferret with two cutaneous masses, presenting 4 months apart and a 7-year-old spayed female ferret with two cutaneous masses, that appeared simultaneously on two locations are presented. In the first patient, both masses were diagnosed as mast cell tumours, and in the second patient, squamous papilloma and sebaceous adenoma were diagnosed. One session of ECT with bleomycin injected intratumourally was applied in all tumours. Results Complete response (CR) of all tumours was obtained, without recurrence during observation period of 15 months after ECT for first tumour and 11 months after ECT of the tumour located on the right hock in first patient, and 8 months after treatment for the second patient. Conclusions In present study, ECT with bleomycin proved to be safe and effective against different cutaneous tumours in ferrets. Due of good results, low cost and relatively easy procedure, ECT could be the treatment of choice instead of surgery for the selected skin tumours in ferrets.
Published in DiRROS: 11.06.2024; Views: 288; Downloads: 195
Full text (1,59 MB)
This document has many files! More... |
1608. In silico selection approach to develop DNA aptamers for a stem-like cell subpopulation of non-small lung cancer adenocarcinoma cell line A549Mateja Vidic, Tina Šmuc, Nikolaja Janež, Michael Blank, Tomaž Accetto, Jan Mavri, Isis Nascimento, Arthur A. Nery, Henning Ulrich, Tamara Lah Turnšek, 2018, original scientific article Published in DiRROS: 11.06.2024; Views: 256; Downloads: 138
Full text (565,49 KB)
This document has many files! More... |
1609. Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage : a single institution experienceNikola Bešić, Marta Dremelj, Gašper Pilko, 2018, original scientific article Abstract: Locoregional recurrence is common in patients with locally advanced differentiated thyroid carcinoma (DTC). Our aim was to find out the rate of locoregional control of the disease after external beam radiotherapy (EBRT) of the neck and mediastinum in patients with DTC and pT4 tumor. Patients and methods Altogether 91 patients (47 males, 44 females, median age 61 years) with DTC had EBRT of the neck and mediastinum as part of the multimodal treatment of pT4 tumor (63 cases pT4a, 28 cases pT4b) from the year 1973 to 2015. Data on clinical factors, histopathology and recurrence were collected. Disease-free, disease-specific and overall survival was calculated. Results Median tumor size was 5 cm (range 1%30 cm). Out of 91 patients, 23 had distant and 38 regional metastases. A total or near-total thyroidectomy, lobectomy, subtotal thyroidectomy and lymph node dissection was performed in 70%, 14%, 2% and 30% of cases, respectively. Thirteen percent of patients were not treated with surgery. All patients had EBRT and 39 had chemotherapy. Radioiodine (RAI) ablation of thyroid remnant and RAI therapy was applied in 90% and 40% of cases, respectively. Recurrence was diagnosed in 29/64 patients without a persistent disease: locoregional and distant in 16 and 13 cases, respectively. Five-year and ten-year disease-free survival rate was 64% and 48%, respectively. Conclusions The majority of patients with DTC and pT4 tumors who were treated with EBRT of the neck and mediastinum region as part of multimodal treatment have long-lasting locoregional control of the disease.
Keywords: thyroid carcinoma, radiotherapy, survival, pathology
Published in DiRROS: 11.06.2024; Views: 347; Downloads: 108
Full text (300,30 KB) |
1610. Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cellsTanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Čemažar, Laurence Le Moyec, Antoine F. Carpentier, Philippe Savarin, Janja Ocvirk, 2018, original scientific article Abstract: Malignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the metabolic effects of bevacizumab on the glioma cells carrying the IDH1 mutation, a mutation, associated with better prognosis and treatment outcome. Bevacizumab is known to inhibit tumour growth by neutralizing the biological activity of vascular endothelial growth factor (VEGF). However, the direct effects of bevacizumab on tumour cells metabolism remain poorly known. Materials and methods The immunoassay and MTT assay were used to assess the concentration of secreted VEGF and cell viability after bevacizumab exposure. Metabolomic studies on cells were performed using high resolution magic angle spinning spectroscopy (HRMAS). Results mIDH1-U87 cells secreted VEGF (13 ng/mL). Regardless, bevacizumab had no cytotoxic effect, even after a 72h exposure and with doses as high as 1 mg/mL. Yet, HRMAS analysis showed a significant effect of bevacizumab (0.1 mg/mL) on the metabolic phenotype of mIDH1-U87 cells with elevation of 2-hydroxyglutarate and changes in glutamine group metabolites (alanine, glutamate, glycine) and lipids (polyunsaturated fatty acids [PUFA], glycerophosphocholine, and phosphocholine). Conclusions In mIDH1-U87 cells, changes in glutamine group metabolites and lipids were identified as metabolic markers of bevacizumab treatment. These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.
Keywords: symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer, idh1 mutation, malignant glioma, bevacizumab, metabolic fingerprint
Published in DiRROS: 11.06.2024; Views: 296; Downloads: 128
Full text (511,70 KB) |
